Loading…

The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma

Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. Design: Retrospective study of 54 patients with either diffuse large cell or...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1993-01, Vol.4 (1), p.51-54
Main Authors: Romaguera, J. E., Pugh, W., Luthra, R., Goodacre, A., Cabanillas, F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3
cites cdi_FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3
container_end_page 54
container_issue 1
container_start_page 51
container_title Annals of oncology
container_volume 4
creator Romaguera, J. E.
Pugh, W.
Luthra, R.
Goodacre, A.
Cabanillas, F.
description Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. Design: Retrospective study of 54 patients with either diffuse large cell or immunoblastic lymphoma who had cytogenetics and/or molecular studies performed. Results: Patient characteristics, complete remission rate, and time to treatment failure (TTF) were similar at three year follow-up for groups with and without t(14; 18)/BCL-2R Survival was worse for the former but the difference was not statistically significant. For DEL 6q, patient characteristics and survival rates were similar at three year follow-up for patients with and without the abnormality. TTF was worse for the former but this was not statistically significant. Conclusion: This study, with equal or greater number of patients with t(14; 18) than previous reports, fails to show a worse prognosis for patients with the t(14; 18) chromosomal abnormality. A definite association will await further accrual of patients and a meaningul multivariate analysis.
doi_str_mv 10.1093/oxfordjournals.annonc.a058361
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75584295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75584295</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3</originalsourceid><addsrcrecordid>eNpVkF1rFDEUhoModVv9CUJuFHsx23zPBOmFbmsrLIiwoHgTMpOTNnUm2SYz0oI_3qm7LHh1Lp73fD0IvaVkSYnmZ-nBp-zu0pSj7cvSxphit7RENlzRZ2hBpdJVQwR9jhZEM17VkouX6LiUO0KI0kwfoaNGcMkVX6A_m1vAXR9i6GyPM_Tw28YOcPJ4fE_FB0yb07NPq3XFZmhztvEGBogjttHhi8s1Vvc4ROyC91MB3Nt8M8-Dvsf947C9TYP9lwzDMMXU9raMoTugV-iFn3-A1_t6gjafLzer62r99erL6uO66gTlY9Vw6730tPHag-6kcpIT1TqQTrRggXIG4KQQreCq5co1wBivQTCoNbT8BL3bjd3mdD9BGc0QytONNkKaiqmlbATTcg6e74JdTqVk8Gabw2Dzo6HEPMk3_8s3O_lmL3_uf7NfNLUDuEP33vbMqx0PZYSHA7b5l1E1r6W5_vHTrPR3dlV_Y-aC_wU0q5gV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75584295</pqid></control><display><type>article</type><title>The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma</title><source>Oxford University Press Archive</source><creator>Romaguera, J. E. ; Pugh, W. ; Luthra, R. ; Goodacre, A. ; Cabanillas, F.</creator><creatorcontrib>Romaguera, J. E. ; Pugh, W. ; Luthra, R. ; Goodacre, A. ; Cabanillas, F.</creatorcontrib><description>Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. Design: Retrospective study of 54 patients with either diffuse large cell or immunoblastic lymphoma who had cytogenetics and/or molecular studies performed. Results: Patient characteristics, complete remission rate, and time to treatment failure (TTF) were similar at three year follow-up for groups with and without t(14; 18)/BCL-2R Survival was worse for the former but the difference was not statistically significant. For DEL 6q, patient characteristics and survival rates were similar at three year follow-up for patients with and without the abnormality. TTF was worse for the former but this was not statistically significant. Conclusion: This study, with equal or greater number of patients with t(14; 18) than previous reports, fails to show a worse prognosis for patients with the t(14; 18) chromosomal abnormality. A definite association will await further accrual of patients and a meaningul multivariate analysis.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/oxfordjournals.annonc.a058361</identifier><identifier>PMID: 8435363</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; BCL-2 ; Chromosome Deletion ; Chromosomes, Human, Pair 14 ; Chromosomes, Human, Pair 6 ; cytogenetics ; DEL 6q ; Female ; Follow-Up Studies ; Gene Rearrangement - genetics ; Humans ; Karyotyping ; lymphoma ; Lymphoma, Large B-Cell, Diffuse - genetics ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Remission Induction ; Translocation, Genetic - genetics ; Treatment Failure</subject><ispartof>Annals of oncology, 1993-01, Vol.4 (1), p.51-54</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3</citedby><cites>FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8435363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romaguera, J. E.</creatorcontrib><creatorcontrib>Pugh, W.</creatorcontrib><creatorcontrib>Luthra, R.</creatorcontrib><creatorcontrib>Goodacre, A.</creatorcontrib><creatorcontrib>Cabanillas, F.</creatorcontrib><title>The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. Design: Retrospective study of 54 patients with either diffuse large cell or immunoblastic lymphoma who had cytogenetics and/or molecular studies performed. Results: Patient characteristics, complete remission rate, and time to treatment failure (TTF) were similar at three year follow-up for groups with and without t(14; 18)/BCL-2R Survival was worse for the former but the difference was not statistically significant. For DEL 6q, patient characteristics and survival rates were similar at three year follow-up for patients with and without the abnormality. TTF was worse for the former but this was not statistically significant. Conclusion: This study, with equal or greater number of patients with t(14; 18) than previous reports, fails to show a worse prognosis for patients with the t(14; 18) chromosomal abnormality. A definite association will await further accrual of patients and a meaningul multivariate analysis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>BCL-2</subject><subject>Chromosome Deletion</subject><subject>Chromosomes, Human, Pair 14</subject><subject>Chromosomes, Human, Pair 6</subject><subject>cytogenetics</subject><subject>DEL 6q</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Rearrangement - genetics</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Remission Induction</subject><subject>Translocation, Genetic - genetics</subject><subject>Treatment Failure</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNpVkF1rFDEUhoModVv9CUJuFHsx23zPBOmFbmsrLIiwoHgTMpOTNnUm2SYz0oI_3qm7LHh1Lp73fD0IvaVkSYnmZ-nBp-zu0pSj7cvSxphit7RENlzRZ2hBpdJVQwR9jhZEM17VkouX6LiUO0KI0kwfoaNGcMkVX6A_m1vAXR9i6GyPM_Tw28YOcPJ4fE_FB0yb07NPq3XFZmhztvEGBogjttHhi8s1Vvc4ROyC91MB3Nt8M8-Dvsf947C9TYP9lwzDMMXU9raMoTugV-iFn3-A1_t6gjafLzer62r99erL6uO66gTlY9Vw6730tPHag-6kcpIT1TqQTrRggXIG4KQQreCq5co1wBivQTCoNbT8BL3bjd3mdD9BGc0QytONNkKaiqmlbATTcg6e74JdTqVk8Gabw2Dzo6HEPMk3_8s3O_lmL3_uf7NfNLUDuEP33vbMqx0PZYSHA7b5l1E1r6W5_vHTrPR3dlV_Y-aC_wU0q5gV</recordid><startdate>199301</startdate><enddate>199301</enddate><creator>Romaguera, J. E.</creator><creator>Pugh, W.</creator><creator>Luthra, R.</creator><creator>Goodacre, A.</creator><creator>Cabanillas, F.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199301</creationdate><title>The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma</title><author>Romaguera, J. E. ; Pugh, W. ; Luthra, R. ; Goodacre, A. ; Cabanillas, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>BCL-2</topic><topic>Chromosome Deletion</topic><topic>Chromosomes, Human, Pair 14</topic><topic>Chromosomes, Human, Pair 6</topic><topic>cytogenetics</topic><topic>DEL 6q</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Rearrangement - genetics</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Remission Induction</topic><topic>Translocation, Genetic - genetics</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romaguera, J. E.</creatorcontrib><creatorcontrib>Pugh, W.</creatorcontrib><creatorcontrib>Luthra, R.</creatorcontrib><creatorcontrib>Goodacre, A.</creatorcontrib><creatorcontrib>Cabanillas, F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romaguera, J. E.</au><au>Pugh, W.</au><au>Luthra, R.</au><au>Goodacre, A.</au><au>Cabanillas, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>1993-01</date><risdate>1993</risdate><volume>4</volume><issue>1</issue><spage>51</spage><epage>54</epage><pages>51-54</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimed to impart a worse rate of complete remission and disease-free survival in diffuse large cell lymphoma (DLCL). DEL 6q has also been associated with poor outcome. Design: Retrospective study of 54 patients with either diffuse large cell or immunoblastic lymphoma who had cytogenetics and/or molecular studies performed. Results: Patient characteristics, complete remission rate, and time to treatment failure (TTF) were similar at three year follow-up for groups with and without t(14; 18)/BCL-2R Survival was worse for the former but the difference was not statistically significant. For DEL 6q, patient characteristics and survival rates were similar at three year follow-up for patients with and without the abnormality. TTF was worse for the former but this was not statistically significant. Conclusion: This study, with equal or greater number of patients with t(14; 18) than previous reports, fails to show a worse prognosis for patients with the t(14; 18) chromosomal abnormality. A definite association will await further accrual of patients and a meaningul multivariate analysis.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>8435363</pmid><doi>10.1093/oxfordjournals.annonc.a058361</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 1993-01, Vol.4 (1), p.51-54
issn 0923-7534
1569-8041
language eng
recordid cdi_proquest_miscellaneous_75584295
source Oxford University Press Archive
subjects Adolescent
Adult
Aged
Aged, 80 and over
BCL-2
Chromosome Deletion
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 6
cytogenetics
DEL 6q
Female
Follow-Up Studies
Gene Rearrangement - genetics
Humans
Karyotyping
lymphoma
Lymphoma, Large B-Cell, Diffuse - genetics
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Remission Induction
Translocation, Genetic - genetics
Treatment Failure
title The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T12%3A24%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20relevance%20of%20t(14;%2018)/BCL-2%20rearrangement%20and%20DEL%206q%20in%20diffuse%20large%20cell%20lymphoma%20and%20immunoblastic%20lymphoma&rft.jtitle=Annals%20of%20oncology&rft.au=Romaguera,%20J.%20E.&rft.date=1993-01&rft.volume=4&rft.issue=1&rft.spage=51&rft.epage=54&rft.pages=51-54&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/oxfordjournals.annonc.a058361&rft_dat=%3Cproquest_cross%3E75584295%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-83aff5f18f9fe9c56d5306bde5d4beae132eed544b436b36d8e2237e42e79eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75584295&rft_id=info:pmid/8435363&rfr_iscdi=true